Indee Labs

Sustainable Development Goals

Challenges

Reach Humanity Scale Healthcare

Team

Mike Nicholls

Co-Investors

Company Briefing

Indee Labs is developing Hydropore the next generation manufacturing process for Immunotherapy Cancer Treatments.

Hydropore™ is a simple, scalable and efficient way to accelerate the discovery, development and manufacturing of gene-modified cell therapies (GMCTs) such as T cell immunotherapies. This novel, non-viral technology utilizes the power of microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene-editing complexes to immune cells in a matter of seconds, yielding millions of high quality cells with negligible impact to cell viability and function. Hydropore™ bypasses the challenges and limitations of viral transduction and traditional transfection via electroporation, allowing companies to accelerate their research goals from discovery to manufacturing.

Website

Related companies